首页> 美国卫生研究院文献>other >Phase I Pharmacokinetic and Pharmacodynamic Study of SJG-136 a Novel DNA Sequence Selective Minor Groove Cross-Linking Agent in advanced solid tumors

【2h】

Phase I Pharmacokinetic and Pharmacodynamic Study of SJG-136 a Novel DNA Sequence Selective Minor Groove Cross-Linking Agent in advanced solid tumors

机译：I期SJG-136的药代动力学和药效学研究一种新型DNA序列选择性次要槽交联剂在先进的实体瘤中

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

PurposeThis phase I study assessed the maximum tolerated dose (MTD), safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of SJG-136, a sequence-specific DNA cross-linking agent, in patients with advanced cancer.

著录项

期刊名称 other
作者
Igor Puzanov; Wooin Lee; Alice P. Chen; M. Wade Calcutt; David. L. Hachey; Wendy L. Vermeulen; Victoria J. Spanswick; Chih-Yi Liao; John A. Hartley; Jordan D. Berlin; Mace L. Rothenberg;
展开▼
作者单位

展开▼
年(卷),期 -1(17),11
年度 -1
页码 3794–3802
总页数 20
原文格式 PDF
正文语种
中图分类
关键词
SJG-136 clinical trial cancer Phase I pharmacokinetics pharmacodynamics;

机译：SJG-136;临床试验;癌症;I期;药代动力学;药效学;

相似文献

外文文献
中文文献
专利

1. Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors. [J] . Puzanov I, Lee W, Chen AP, Clinical cancer research: an official journal of the American Association for Cancer Research . 2011,第11期

机译：SJG-136（一种新型的DNA序列选择性小沟交联剂）在晚期实体瘤中的一期药代动力学和药效学研究。
2. Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors. [J] . Hochhauser D, Meyer T, Spanswick VJ, Clinical cancer research: an official journal of the American Association for Cancer Research . 2009,第6期

机译：晚期实体瘤患者中序列选择性小沟DNA结合剂SJG-136的I期研究。
3. Sequence-Selective Interaction of the Minor-Groove Interstrand Cross-Linking Agent SJG-136 with Naked and Cellular DNA: Footprinting and Enzyme Inhibition Studies [J] . Chris Martin, Tom Ellis, Claire J.McGurk, Biochemistry . 2005,第11期

机译：次槽交叉链接剂SJG-136具有裸露和细胞DNA的序列选择性相互作用：足迹和酶抑制研究
4. PHASE II OPEN-LABEL STUDY OF SINGLE-AGENT HYDROXYUREA FOR TREATMENT OF ADVANCED CUTANEOUS MAST CELL TUMORS IN DOGS [C] . Ken Rassnick, Renee Al-Sarraf, Dennis Bailey, Annual Conference of the Veterinary Cancer Society . 2009

机译：单药羟基脲的第II期开放标签研究，用于治疗犬晚皮腰肿瘤瘤
5. Evaluation of the pharmacokinetic-pharmacodynamic relationship, metabolism and plasma protein binding of the novel antitumor agent, 2-methoxyestradiol (2ME2), following oral administration in patients with solid tumors. [D] . Lakhani, Nehal Jagdish. 2005

机译：实体瘤患者口服后评估新型抗肿瘤药2-甲氧基雌二醇（2ME2）的药代动力学与药效关系，代谢和血浆蛋白结合。
6. Cellular pharmacology of novel C8-linked anthramycin-based sequence-selective DNA minor groove cross-linking agents. [O] . M. Smellie, L. R. Kelland, D. E. Thurston, 1994

机译：新型基于C8连接的蒽霉素的序列选择性DNA小沟交联剂的细胞药理作用。
7. Phase I study of sequence-selective minor groove DNA binding agent SJG-136 in patients with advanced solid tumors [O] . Hochhauser, D., Meyer, T., Spanswick, V.J., 2009

机译：序列选择性小沟DNA结合剂SJG-136在晚期实体瘤患者中的I期研究

Phase I Pharmacokinetic and Pharmacodynamic Study of SJG-136 a Novel DNA Sequence Selective Minor Groove Cross-Linking Agent in advanced solid tumors

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅